IP Library Granted Patent US 11,629,181
Granted Patent B2
US 11,629,181 · App. 17/848,176 · Granted Apr 18, 2023

RSV F protein compositions and methods for making same

Inventors: Kurt Swanson (Newton, MA); Philip R. Dormitzer (Weston, MA)
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
C07K16/1027A61K39/12A61K39/155C07K14/005A61K39/00A61K2039/5252A61K2039/5256A61K2039/5258A61K2039/53A61K2039/55505A61K2039/55555A61K2039/55561A61K2039/55566A61K2039/55572C07K2317/76C07K2319/00C07K2319/21C07K2319/50C07K2319/73C12N2760/18522C12N2760/18534C12N2770/36143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,629,181
App. No.
17/848,176
Granted
Apr 18, 2023
Kind
B2
Abstract

The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

Claims (7)

1. An immunogenic composition comprising a recombinant RSV F polypeptide of a RSV A subgroup and a recombinant RSV F polypeptide of a RSV B subgroup;

wherein the recombinant RSV F polypeptide of the RSV A subgroup and the RSV F polypeptide of the RSV B subgroup comprise a trimerizing sequence from bacteriophage T4 fibritin; and

wherein the recombinant RSV F polypeptide of the RSV A subgroup and the RSV F polypeptide of the RSV B subgroup do not comprise a transmembrane region or cytoplasmic tail.

2. The immunogenic composition of claim 1 , wherein the trimerizing sequence comprises the amino acid sequence of SEQ ID NO: 19.

3. The immunogenic composition of claim 1 , wherein the trimerizing sequence comprises amino acid residues 3-29 of SEQ ID NO: 19.

4. The immunogenic composition of claim 1 , wherein the recombinant RSV F polypeptide of the RSV A subgroup and the recombinant RSV F polypeptide of the RSV B subgroup do not comprise a p27 region.

5. The immunogenic composition of claim 1 , wherein the recombinant RSV F polypeptide of the RSV A subgroup and the recombinant RSV F polypeptide of the RSV B subgroup are soluble.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2022
From: SWANSON, KURT; DORMITZER, PHILIP R.
To: NOVARTIS VACCINES & DIAGNOSTICS, INC.
Reel/Frame 060321/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2022
From: CHIRON CORPORATION
To: NOVARTIS VACCINES & DIAGNOSTICS, INC.
Reel/Frame 060321/0344 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2022
From: NOVARTIS VACCINES & DIAGNOSTICS, INC.
To: NOVARTIS AG
Reel/Frame 060321/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2022
From: NOVARTIS AG
To: GLAXOSMITHKLINE BIOLOGICALS SA
Reel/Frame 060321/0614 →